Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783588 · ClinicalTrials.gov registry record · Phase 1
A Phase I Extension Trial of Repeated Infusions of ISF35
A Phase 1 study, sponsored by Memgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00783588: Completed Phase 1 study, sponsored by Memgen.
NCT00783588 is a Phase 1 study that has completed, run by Memgen. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783588, a Phase 1 study, has completed, sponsored by Memgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study is a Phase Ib extension trial that will assess the toxicity, tolerability, and safety of up to two repeated administrations of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells given intravenously to patients with CLL who tolerated ISF35 in the prior Phase I infusion trial at M.D. Anderson.
Interventions
- BIOLOGICAL ISF35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
What the finished NCT00783588 record still lists
NCT00783588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which ISF35 is the first listed.
NCT00783588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783588 about?
NCT00783588 is a clinical study titled "A Phase I Extension Trial of Repeated Infusions of ISF35". The study is a Phase Ib extension trial that will assess the toxicity, tolerability, and safety of up to two repeated administrations of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells given intravenously to patients with CLL who tolerated ISF35 in the prior Phase I infusion ...
What is the current status of trial NCT00783588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2007-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00783588?
The interventions under investigation include: ISF35 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783588?
This trial is sponsored by Memgen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00783588's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia